Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Test Anal ; 11(7): 950-956, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30865387

ABSTRACT

Formoterol is a long-acting beta2-adrenoceptor agonist (LABA) used for the treatment of asthma and exercise-induced bronchoconstriction. Formoterol is usually administered as a racemic (rac-) mixture of (R,R)- and (S,S)-enantiomers. While formoterol is restricted by the World Anti-Doping Agency (WADA), inhalation of formoterol is permitted to a predetermined dose (54 µg/24 hours) and a urine threshold of 40 ng/mL. However, chiral switch enantiopure (R,R)-formoterol is available, effectively doubling the therapeutic advantage for the same threshold. The aim of this study was to investigate whether formoterol exhibits enantioselective urinary pharmacokinetics following inhalation. Six healthy volunteers were administered a 12 µg inhaled dose of rac-formoterol. Urine was collected over 24 hours and analyzed by enantioselective ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay. Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold. The proportion of conjugation differed between enantiomers with glucuronide conjugation much greater for (R,R)-formoterol (around 30%-60% of total) compared to (S,S)-formoterol (0%-30%). There was clear evidence of inter-individual enantioselectivity observed in the ratios of (R,R):(S,S)-formoterol, where (S,S)- was predominant in free formoterol, and (R,R)- predominant in the conjugated metabolite. In conclusion, rac-formoterol delivered by inhalation exhibits enantioselective elimination in urine following single-dose administration. Enantioselective assays should be employed in doping control to screen for banned beta2-agonist chiral switch products such as (R,R)-formoterol, and total hydrolyzed rac-formoterol is warranted to account for inter-individual differences in enantioselective glucuronidation.


Subject(s)
Adrenergic beta-2 Receptor Agonists/urine , Formoterol Fumarate/urine , Glucuronides/urine , Administration, Inhalation , Adrenergic beta-2 Receptor Agonists/administration & dosage , Adult , Chromatography, High Pressure Liquid , Doping in Sports , Female , Formoterol Fumarate/administration & dosage , Humans , Male , Middle Aged , Stereoisomerism , Substance Abuse Detection/methods , Tandem Mass Spectrometry , Young Adult
2.
Sports Med ; 46(12): 1787-1795, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27164986

ABSTRACT

The World Anti-Doping Agency (WADA) currently allows therapeutic use of the beta2-agonists salbutamol, formoterol and salmeterol when delivered via inhalation despite some evidence suggesting these anti-asthma drugs may be performance enhancing. Beta2-agonists are usually administered as 50:50 racemic mixtures of two enantiomers (non-superimposable mirror images), one of which demonstrates significant beta2-adrenoceptor-mediated bronchodilation while the other appears to have little or no pharmacological activity. For salbutamol and formoterol, urine thresholds have been adopted to limit supratherapeutic dosing and to discriminate between inhaled (permitted) and oral (prohibited) use. However, chiral switches have led to the availability of enantiopure (active enantiomer only) preparations of salbutamol and formoterol, which effectively doubles their urine thresholds and provides a means for athletes to take supratherapeutic doses for doping purposes. Given the availability of these enantiopure beta2-agonists, the analysis of these drugs using enantioselective assays should now become routine. For salmeterol, there is currently only a therapeutic dose threshold and adoption of a urinary threshold should be a high priority for doping control.


Subject(s)
Adrenergic beta-2 Receptor Agonists/administration & dosage , Albuterol/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Athletes , Doping in Sports/prevention & control , Formoterol Fumarate/administration & dosage , Salmeterol Xinafoate/administration & dosage , Administration, Inhalation , Adrenergic beta-2 Receptor Agonists/urine , Albuterol/urine , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Doping in Sports/legislation & jurisprudence , Formoterol Fumarate/urine , Humans , Salmeterol Xinafoate/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...